Marchetti C, Rosati A, Scaletta G, et al. - Researchers investigated the role of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) with BRCA1/2 mutation (BRCAmut) who underwent platinum-based chemotherapy followed by olaparib maintenance. They conducted a case-control study including 46 patients. Among these, 23 (50%) BRCAmut women undergoing SCS followed by platinum-based chemotherapy and olaparib maintenance were matched with 23 (50%) BRCAmut women who only took medical therapy. Outcomes revealed an increased time to first subsequent therapy and postrecurrence survival among BRCAmut patients who underwent SCS before platinum-based chemotherapy and olaparib maintenance. They recommend individualizing indication to SCS.